BMY
Bristol-Myers Squibb Company
Price performance
Sep 18, 2026About
Company activity
17 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 07/30 | BMY | 8-K | Bristol-Myers Squibb Reports Strong Q2 2026 Results and Raises Full-Year Outlook | — | — | — |
| 05/08 | BMY | 8-K | Bristol-Myers Squibb Elects Directors and Approves Key Proposals at Annual Meeting | — | — | — |
| 04/30 | BMY | 8-K | Bristol Myers Squibb Reports 3% Revenue Growth in Q1 2026 | — | — | — |
| 02/05 | BMY | 8-K | Bristol Myers Squibb Reports 2025 Financial Results and Announces Dividend Increase | — | — | — |
| 01/12 | BMY | 8-K | Bristol-Myers Squibb Posts Investor Presentation at J.P. Morgan Healthcare Conference | — | — | — |
| 11/18/25 | BMY | 8-K | Bristol-Myers Squibb Announces Early Settlement of Tender Offers for Debt Refinancing | — | — | — |
| 11/10/25 | BMY | 8-K | Bristol-Myers Squibb Announces Completion of €4.9 Billion Notes Offering | — | — | — |
| 11/03/25 | BMY | 8-K | Bristol-Myers Squibb Launches Tender Offer to Purchase Certain Notes | — | — | — |
| 10/30/25 | BMY | 8-K | Bristol-Myers Squibb Reports Q3 2025 Financial Results and Business Updates | — | — | — |
| 07/31/25 | BMY | 8-K | Bristol Myers Squibb Reports Second Quarter 2025 Financial Results and Raises Guidance | — | — | — |
| 07/25/25 | BMY | 8-K | Bristol Myers Squibb Announces Leadership Transition | — | — | — |
| 05/07/25 | BMY | 8-K | Bristol-Myers Squibb Shareholders Approve Director Elections and Executive Compensation | — | — | — |
| 04/24/25 | BMY | 8-K | Bristol Myers Squibb Reports Strong First Quarter 2025 Results and Raises Guidance | — | — | — |
| 02/18/25 | BMY | 8-K | Bristol-Myers Squibb's General Counsel Announces Retirement | — | — | — |
| 02/06/25 | BMY | 8-K | Bristol-Myers Squibb Reports Strong Fourth Quarter and Full-Year 2024 Results | — | — | — |
| 01/13/25 | BMY | 8-K | Bristol-Myers Squibb Discloses Strategic Focus and Pipeline Updates | — | — | — |
| 10/31/24 | BMY | 8-K | Bristol-Myers Squibb Reports Q3 2024 Financial Results and Raises Guidance | — | — | — |
BMY filing record
Bristol-Myers Squibb Company (BMY): 17 8-K filings summarized, the most recent on Jul 30, 2026.
What the 8-K filings said
- Jul 30, 2026 · high impact
Bristol-Myers Squibb reported a 6% increase in second-quarter 2026 revenues to $13.0 billion, with a 15% growth in its Growth Portfolio to $7.6 billion. The company reported GAAP EPS of $1.62 and non-GAAP EPS of $2.04. The company raised its full-year revenue guidance to a range of $49.0 billion to $50.0 billion and…
Bristol-Myers Squibb Reports Strong Q2 2026 Results and Raises Full-Year Outlook - May 8, 2026 · medium impact
At the Annual Meeting held on May 5, 2026, Bristol-Myers Squibb Company's shareholders elected all 11 nominees to the board of directors, approved the compensation of named executive officers, ratified the appointment of Deloitte & Touche LLP as the independent auditor, and approved the 2026 stock award and incentive…
Bristol-Myers Squibb Elects Directors and Approves Key Proposals at Annual Meeting - Apr 30, 2026 · medium impact
Bristol Myers Squibb reported a 3% increase in total revenues for the first quarter of 2026, reaching $11.5 billion. The Growth Portfolio saw a 12% rise in revenues, driven by strong performance from products like Camzyos, Breyanzi, and Reblozyl. The Legacy Portfolio, however, experienced a 6% decline in revenues. The…
Bristol Myers Squibb Reports 3% Revenue Growth in Q1 2026 - Feb 5, 2026 · high impact
Bristol Myers Squibb reported its financial results for the fourth quarter and full year of 2025, showing a 1% increase in total revenues to $12.5 billion and a significant rise in GAAP EPS from $0.04 to $0.53. The company's Growth Portfolio revenues increased by 16% to $7.4 billion, driven by strong performance in…
Bristol Myers Squibb Reports 2025 Financial Results and Announces Dividend Increase - Jan 12, 2026 · low impact
On January 12, 2026, Bristol-Myers Squibb Company posted an investor presentation to its website, discussing its strategic business development, pipeline advancements, and financial discipline. The presentation included forward-looking statements and outlined key next-wave early-stage data and potential new product…
Bristol-Myers Squibb Posts Investor Presentation at J.P. Morgan Healthcare Conference
SEC filings in the last five years
- 54 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A